Daiichi Sankyo discontinues pactimibe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Japanese firm is discontinuing its atherosclerosis agent pactimibe following the ACAT inhibitor's failure to show a significant effect in a 534-patient coronary intravascular ultrasound study. The primary endpoint was change from baseline in percent atheroma volume at 18 months. Secondary measures "showed a lower effect of pactimibe on atherosclerosis than standard of care alone and no beneficial effect on the frequency of cardiovascular events," Daiichi says Oct. 26. "As a result, all ongoing clinical studies with pactimibe will be discontinued." The company plans to present an expanded analysis at the American Heart Association's Scientific Sessions Nov. 15...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.